Back to Search
Start Over
Radiosensitizing potential of the selective cyclooygenase-2 (COX-2) inhibitor meloxicam on human glioma cells.
- Source :
- Journal of Neuro-Oncology; Oct2007, Vol. 85 Issue 1, p25-31, 7p
- Publication Year :
- 2007
-
Abstract
- Abstract  The COX-2 protein is frequently overexpressed in human malignant gliomas. This expression has been associated with their aggressive growth characteristics and poor prognosis for patients. Targeting the COX-2 pathway might improve glioma therapy. In this study, the effects of the selective COX-2 inhibitor meloxicam alone and in combination with irradiation were investigated on human glioma cells in vitro. A panel of three glioma cell lines (D384, U87 and U251) was used in the experiments from which U87 cells expressed constitutive COX-2. The response to meloxicam and irradiation (dose-range of 0â6 Gy) was determined by the clonogenic assay, cell proliferation was evaluated by growth analysis and cell cycle distribution by FACS. 24â72 h exposure to 250â750 μM meloxicam resulted in a time and dose dependent growth inhibition with an almost complete inhibition after 24 h for all cell lines. Exposure to 750 μM meloxicam for 24 h increased the fraction of cells in the radiosensitive G2/M cell cycle phase in D384 (18â27%) and U251 (17â41%) cells. 750 μM meloxicam resulted in radiosensitization of D384 (DMF:2.19) and U87 (DMF:1.25) cells, but not U251 cells (DMF:1.08). The selective COX-2 inhibitor meloxicam exerted COX-2 independent growth inhibition and radiosensitization of human glioma cells. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 0167594X
- Volume :
- 85
- Issue :
- 1
- Database :
- Complementary Index
- Journal :
- Journal of Neuro-Oncology
- Publication Type :
- Academic Journal
- Accession number :
- 26589342
- Full Text :
- https://doi.org/10.1007/s11060-007-9385-4